Is Biogen Inc. overvalued?

Biogen Inc. (BIIB) looks overvalued — trading about 10% above its fair value.

Overvalued

Price

$253.40

Fair value

$229.21

Current P/E

28.7

Normal P/E

26.0

Market cap

$37.46B

Dividend yield

0.0%

Return on equity

1.9%

Sector

Healthcare

Fair value compares BIIB's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks